Targeting TGF-beta Superfamily Biology
Best-In-Class Ligand Traps for Diseases of High Unmet Medical Need
OUR COMPANY
Connecting science and passion to deliver
transformative therapies
35Pharma is a biopharmaceutical company that designs and develops
innovative biologics for diseases of high unmet medical need.
We believe in connecting rigorous science with our innate sense of urgency to
rapidly generate breakthrough therapies for patients in need of a better quality of life.
Our highly qualified team of drug developers and company builders has a
track record of advancing complex biologics from discovery through clinical trials.
OUR APPROACH
Rational design fueled by
years of experience
Our strength is combining superior protein engineering
expertise with a deep understanding of TGF-beta structure-function
relationships to rationally design highly potent ligand traps.
Our in-house team of experienced manufacturing scientists
rigorously evaluates all drug candidates to ensure excellent
manufacturability as part of candidate selection.
LEADERSHIP
Our Leadership Team and Board of Directors combine years of experience in developing complex biologics with a successful track record in company creation, private and public financings, as well as Pharma partnerships.
Learn more below!
JOIN US
A mission to radically transform
patients’ lives
We believe in building effective teams that value taking action on the best ideas
to develop new breakthrough therapies at industry leading pace. Our beautiful
20,000 square feet R&D facilities are located in the heart of Montreal, Canada,
and comprise laboratory space for pre-clinical research as well as process
development that bolster our mission to serve patients in need.
Read Our Latest News
35Pharma Announces Oral Presentation of HS235 Pre-Clinical Data in Obese HFpEF at ObesityWeek® 2024
Montreal, QC, Canada (Nov 03, 2024) – 35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today announced that it has been selected for an oral presentation at ObesityWeek® 2024 in San Antonio, TX, USA (Nov 3-6, 2024). HS235 is an Fc-fused ligand trap that selectively and potently neutralizes pathological Activins and growth differentiation factors […]
35Pharma Cleared to Initiate Clinical Development of HS235, Novel Activin and GDF Inhibitor for Cardiometabolic Disease and Obesity
Montreal, QC, Canada (Oct 18, 2024) – 35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today announced it received a No Objection Letter from Health Canada for its Clinical Trial Application to initiate HS235-001, a Phase 1 study of HS235 in overweight and obese healthy subjects. “HS235 selectively and potently neutralizes pathological Activins and […]
35Pharma Announces Participation at Upcoming Investor Conferences
Montreal, QC, Canada (June 19, 2024) – 35Pharma, a clinical-stage biopharmaceutical company that designs and develops TGF-beta superfamily therapeutics, today announced it will be participating at the following investor conferences: Leerink Partners Private Company Connect Piper Sandler 2nd Annual Virtual Obesity Day Fireside Chat About 35Pharma 35Pharma is a clinical-stage biopharmaceutical company specializing in TGF-beta superfamily therapeutics for the […]